Case series shows IL-6 receptor blockade as effective therapy in AQP4+NMOSD and MOGAD, suggesting a potential rescue treatment.
This case series describes multicenter experience with interleukin 6 (IL-6) receptor blockers used during attacks in aquaporin 4–immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD).
No takes yet. Share an insight, caveat, or question.
A et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: